PACIRA PHARMS INC
SpecialtyPACIRA PHARMS INC is a specialty pharmaceutical company focused on Immunology. Key products include EXPAREL.
PACIRA PHARMS INC at a Glance
- Fast trial execution (7 months median completion)
PACIRA PHARMS INC's Key Drugs
PACIRA PHARMS INC's core commercial portfolio centers on EXPAREL, ZILRETTA, spanning Immunology — its most strategically important drugs approved in the last 15 years.
PACIRA PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for PACIRA PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
PACIRA PHARMS INC's Therapeutic Areas
PACIRA PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PACIRA PHARMS INC's Top Competitors
PACIRA PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PACIRA PHARMS INC Pipeline Snapshot
Active clinical trials for PACIRA PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • EXPAREL leads revenue
- • 2 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 15/19 completed
- • Speed: 7 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges